Crushed Prasugrel significantly Lowers Platelet Activity In Patients undergoing PCI: Study

When crushed Prasugrel is administered to patients with suspected STEMI, it significantly lowered the platelet activity.;

Written By : MD Bureau

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2021-07-06 05:00 GMT | Update On 2023-10-09 11:30 GMT

When crushed Prasugrel is administered to patients undergoing Primary Percutaneous Coronary Intervention, it significantly lowered the platelet activity, according to a study published in the Journal of the American College of Cardiology.

ST-segment elevation myocardial infarction (STEMI) is the term cardiologists use to describe a classic heart attack. It is one type of myocardial infarction in which a part of the heart muscle (myocardium) has died due to the obstruction of blood supply to the area. As a treatment strategy, STEMI patients are directly taken to the cardiac catheterization laboratory to undergo mechanical revascularization. This is called Primary Percutaneous Coronary Intervention. Anti-platelet therapy is given to such patients. However, the onset of action varies according to the formulation administered.

With this background, Dr. Ashish Kumar Aggarwal carried out a study to compare the pharmacodynamic effects of prasugrel in crushed versus integral tablet formulation in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI).

The trial randomized 441 patients with suspected STEMI and they were given crushed or integral prasugrel 60-mg loading dose in the ambulance. Pharmacodynamic measurements were performed at 4 time points: before antiplatelet treatment, at the beginning and end of pPCI, and 4 h after study treatment onset. The primary endpoint was high platelet reactivity at the end of pPCI. The secondary endpoint was impact of platelet reactivity status on markers of coronary reperfusion.

The study showed some interesting results:

In patients with crushed prasugrel, the occurrence of high platelet reactivity at the end of pPCI was reduced by almost one-half (crushed 34.7% vs. uncrushed 61.6%; odds ratio [OR] = 0.33; 95% confidence interval [CI] = 0.22 to 0.50; p < 0.01).

Platelet reactivity <150 P2Y12 reactivity units at the beginning of coronary angiography correlated with improved Thrombolysis In Myocardial Infarction flow grade 3 in the infarct artery pre-pPCI (OR: 1.78; 95% CI: 1.08 to 2.94; p = 0.02) but not ST-segment resolution (OR: 0.80; 95% CI: 0.48 to 1.34; p = 0.40).

The results of this study demonstrate that pre-hospital administration of crushed prasugrel significantly lowers platelet reactivity before and after pPCI in patients presenting with STEMI.

"However, a considerable number of patients still exhibit inadequate platelet inhibition at the end of pPCI, suggesting the need for alternative agents to bridge the gap in platelet inhibition," the investigators concluded.

Reference:

Study titled, "Pharmacodynamic Effects of Pre-Hospital Administered Crushed Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction," published in the Journal of the American College of Cardiology.

DOI: https://doi.org/10.1016/j.jcin.2021.04.022

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

MD Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Crushed Prasugrel significantly Lowers Platelet Activity In Patients undergoing PCI: Study

When crushed Prasugrel is administered to patients with suspected STEMI, it significantly lowered the platelet activity.;

Similar News

Medical Bulletin 05/Jul/2025

USFDA grants priority review for Winrevair label update based on ZENITH Trial: Merck

SCOT-HEART 2 Trial: CT Angiography Boosts Lifestyle Changes and Preventive Therapy in Cardiovascular Care

How COVID-19 Pandemic Increased Mental Health Issues, Malaria, and Heart Disease? Study Sheds Light

Hypertensive Pregnancy Disorders Linked to Long-Term Cardiovascular Risk in Women with Type 1 Diabetes: Study

Proton Pump Inhibitor Use Linked to Hypertension Risk in Menopausal Women, reveals AHA study

FIB-4 Score Linked to Higher Mortality in Coronary Artery Disease, ISCHEMIA Trial Finds

First oral drug shows promise for Barth syndrome heart and muscle symptoms in new study